New approach to mental disorders systematics: starting point or point of view?
https://doi.org/10.31363/2313-7053-2020-3-3-10
Abstract
The search for new approaches to the mental disordersclassification is one of the priority tasks in modern psychiatry. Current approaches evaluate mental disorders in isolation, ignoring the fact that they are a multisystem pathology that affects not only mental functions, but also a wide range of somatic manifestations. However, there is more and more reason to consider mental disorders as multisystem diseases. This approach is of interest not only for explaining the high comorbidity of somatic and mental disorders, but also in studying the pathophysiological mechanisms that determine the risks and course of multisystem diseases. This strategy can be the basis for the fundamentally new approaches to the systematics of mental disorders with both theoretical and practical significance. To integratesuch an approach, it is necessary to determine the “starting point”, which may be the evaluation of mental disorders andinherited metabolic disorders interaction.
About the Authors
N. G. Neznanov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
I.P. Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
Saint-Petersburg
G. V. Rukavishnikov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Saint-Petersburg
E. D. Kaysanov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Saint-Petersburg
T. V. Zhilyaeva
Federal State Budgetary Educational Institution of Higher Education Privolzhsky Research Medical University of Russian Ministry of Healthcare
Russian Federation
Russian Federation
Nizhnij Novgorod
G. E. Mazo
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Saint-Petersburg
References
1. Neznanov N.G. Depressiya i risk razvitiya somaticheskih zabolevanij Rukovodstvo dlya vrachej. Pod red. N.G. Neznanova, G.E. Mazo, A.O. Kibitov. Moskva: Special’noe izdatel’stvo medicinskih knig. 2019:248. (In Russ.).
2. Neznanov NG, Kozlova SN, Mazo GE, Shlyakhto NG, Smirnov BI. Comorbidity of depressive disorders and coronary heart disease: general aspects of pathogenesis. Zhurnal Nevrologii I Psikhiatrii im. S.S. Korsakova. 2015; 115(5):20-26 (In Russ.). doi: 10.17116/jnevro20151155120-26
3. Rukavishnikov GV, Kibitov AO, Mazo GE, Neznanov NG. Genetic comorbidity of depression and somatic disorders. Zhurnal Nevrologii I Psikhiatrii im. S.S. Korsakova. 2019; 119(1):89-96. (In Russ.). doi: 10.17116/jnevro201911901189
4. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety. 2009; 26(7):607– 611. doi: 10.1002/da.20589
5. Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013; 161(6):832–842. doi:10.1111/bjh.12335
6. Baeza-Velasco C, Pailhez G, Bulbena A, Bagh- dadli A. Joint hypermobility and the heritable dis- orders of connective tissue: clinical and empirical evidence of links with psychiatry. Gen Hosp Psychiatry. 2015; 37(1):24–30. doi:10.1016/j.genhosppsych.2014.10.002
7. Clark LA, Cuthbert B, Lewis-Fernández R et al. Three approaches to understanding and classifying mental disorder: ICD-11, DSM-5, and the National Institute of Mental Health’s Research Domain Criteria (RDoC). Psychol Sci Public Interest. 2017; 18:72-145. doi: 10.1177/1529100617727266
8. Conway CC, Forbes MK, Forbush KT, et al. A Hierarchical Taxonomy of Psychopathology Can Transform Mental Health Research. PerspectPsychol Sci. 2019; 14(3):419–436. doi:10.1177/1745691618810696
9. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3, 211, 768 patients and 113, 383, 368 controls. World Psychiatry. 2017; 16:163–80. doi: 10.1002/wps.20420
10. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013; 170:324–33. doi: 10.1176/appi.ajp.2012.12050599
11. Cuthbert BN, Kozak MJ. Constructing constructs for psychopathology: the NIMH research domain criteria. J Abnorm Psychol. 2013; 122(3):928–937. doi:10.1037/a0034028
12. Demily C, Sedel F. Psychiatric manifestations of treatable hereditary metabolic disorders in adults. Ann Gen Psychiatry. 2014; 13:27. doi:10.1186/s12991-014-0027-x
13. Dipple KM, McCabe ER. Phenotypes of patients with «simple» Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet. 2000; 66(6):1729–1735. doi:10.1086/302938
14. Estrov Y, Scaglia F, Bodamer OA. Psychiatric symptoms of inherited metabolic disease. J Inherit Metab Dis. 2000; 23(1):2–6. doi:10.1023/a:1005685010766
15. Fusar-Poli P., Solmi M., Brondino N., Davies C., Chae C., Politi P., Borgwardt S., Lawrie SM, Parnas J, McGuire P. Transdiagnostic psychiatry: a systematic review. World Psychiatry. 2019; 18(2):192–207. doi: 10.1002/wps.20631
16. Ganesh S, Ahmed P H, Nadella RK, et al. Exome sequencing in families with severe mental illness identifies novel and rare variants in genes implicated in Mendelian neuropsychiatric syndromes. Psychiatry ClinNeurosci. 2019; 73(1):11–19. doi:10.1111/pcn.12788
17. Herrera PM, Vélez Van Meerbeke A, Bonnot O. Psychiatric Disorders Secondary to Neurometabolic Disorders. Trastornospsiquiátricossecundariosaenfermedadesneurometabólicas. Rev ColombPsiquiatr. 2018; 47(4):244–251. doi:10.1016/j.rcp.2017.05.004
18. Jinnah HA, Sabina RL, Van Den Berghe G. Metabolic disorders of purine metabolism affecting the nervous system. HandbClin Neurol. 2013; 113:1827–1836. doi:10.1016/B978-0-444-59565-2.00052-6
19. Johnstone EC, Cooling NJ, Frith CD, Crow TJ, Owens DG. Phenomenology of organic and func- tional psychoses and the overlap between them. Br J Psychiatry. 1988; 153:770–776. doi:10.1192/bjp.153.6.770
20. Kamens SR, Robbins BD, Flanagan EH. Introduction to the Special Issues on Diagnostic Alternatives. Journal of Humanistic Psychology. 2017: 57(6):567–572. doi: 10.1177/0022167817701253
21. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996; 30:17–30.
22. Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One. 2011; 6(9):e24597. doi:10.1371/journal.pone.0024597
23. Maes M, Leonard B, Fernandez A, et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. ProgNeuropsychopharmacolBiol Psychiatry. 2011; 35(3):659–663. doi:10.1016/j.pnpbp.2011.02.019
24. Maj M. Why the clinical utility of diagnostic categories in psychiatry is intrinsically limited and how we can use new approaches to complement them. World Psychiatry. 2018; 17(2):121-122.doi:10.1002/wps.20512
25. Manouilenko I, Eriksson JM, Humble MB, Bejerot S. Minor physical anomalies in adults with autism spectrum disorder and healthy controls. Autism Res Treat. 2014; 2014:743482. doi:10.1155/2014/743482
26. McAllister-Williams RH, Anderson IM, Finkelmeyer A, et al. and the ADD Study Team. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry. 2015; 3(2):117-27. doi: 10.1016/S2215-0366(15)00436-8
27. Millon T. Contemporary directions in psychopathology: scientific foundations of the DSM-V and ICD-11/ edited by T. Millon, R.F. Krueger, E. Simonsen. NY: The Guilford Press, 2010; 3-97:223- 242, 263-275.
28. Mothi SS, Tandon N, Padmanabhan J, et al. Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. Schizophr Res. 2015; 165(1):103–107. doi:10.1016/j.schres.2015.03.034
29. National Institute of Mental Health. Sensorimotor Domain Added to the RDoC Framework. January 14, 2019. Retrieved from: https://www.nimh.nih.gov/news/science-news/2019/sensorimotor-domainadded-to-the-rdoc-framework.shtml
30. Pillinger T, D’Ambrosio E, McCutcheon R, Howes OD. Is psychosis a multisystem disorder? A metareview of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models [published correction appears in Mol Psychiatry. Mol Psychiatry. 2019; 24(6):776–794. doi:10.1038/s41380-018-0058-9
31. Reininghaus U, Böhnke JR, Chavez‐Baldini UY, Gibbons R, Ivleva E, Clementz BA, Pearlson GD, Keshavan MS, Sweeney JA and Tamminga CA. Transdiagnostic dimensions of psychosis in the Bipolar‐Schizophrenia Network on Intermediate Phenotypes (B‐SNIP). World Psychiatry. 2019; 18(1):67-76. doi: 10.1002/wps.20607
32. Salloum IM. Psychiatric Diagnosis: Challenges and Prospects/ edited by Ihsan M. Salloum and Juan E. Mezzich. UK: John Wiley & Son. 2009; 1-29: 187-213, 219-262.
33. Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007; 30(5):631–641. doi:10.1007/s10545-007-0661-4
34. Sidransky E. Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet. 2006; 70(4):275–282. doi:10.1111/j.1399-0004.2006.00688.x
35. Stegink LD, Koch R, Blaskovics ME, Filer LJ Jr, Baker GL, McDonnell JE. Plasma phenylalanine levels in phenylketonuric heterozygous and normal adults administered aspartame at 34 mg/ kg body weight. Toxicology. 1981; 20(1):81–90. doi:10.1016/0300-483x(81)90108-6
36. Tishler PV, Woodward B, O’Connor J, et al. High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry. 1985; 142(12):1430–1436. doi:10.1176/ajp.142.12.1430
37. Van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry. 2016; 15(2):118-24. doi: 10.1002/wps.20310
38. Vieta E, Phillips ML. Deconstructing bipolar disorder: a critical review of its diagnostic validity and a proposal for DSM-V and ICD-11. Schizophr Bull. 2007; 33(4):886–892. doi:10.1093/schbul/sbm057
39. Vockley J. Metabolism as a complex genetic trait, a systems biology approach: implications for inborn errors of metabolism and clinical diseases. J Inherit Metab Dis. 2008; 31(5):619–629. doi:10.1007/s10545-008-1005-8
40. Weinberg SM, Jenkins EA, Marazita ML, Maher BS. Minor physical anomalies in schizophrenia: a meta-analysis. Schizophr Res. 2007; 89(1-3):72–85. doi:10.1016/j.schres.2006.09.002
41. Xu T, Chan RC, Compton MT. Minor physical anomalies in patients with schizophrenia, unaffected first-degree relatives, and healthy controls: a meta-analysis. PLoS One. 2011; 6(9):e24129. doi:10.1371/journal.pone.0024129
42. Zajecka JM, Fava M, Shelton RC, Barrentine LW, Young P, Papakostas GI. Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors. The Journal of Clinical Psychiatry. 2016; 77(5):654–660. doi:10.4088/jcp.15m10181
Review
For citations:
Neznanov N.G., Rukavishnikov G.V., Kaysanov E.D., Zhilyaeva T.V., Mazo G.E. New approach to mental disorders systematics: starting point or point of view? V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2020;(3):3-10. (In Russ.) https://doi.org/10.31363/2313-7053-2020-3-3-10
Views:
1165
Email this article 